CARR EDWARD 4
4 · Dianthus Therapeutics, Inc. /DE/ · Filed Mar 13, 2026
Research Summary
AI-generated summary of this filing
Dianthus (DNTH) Chief Accounting Officer Edward Carr Exercises Options, Sells Shares
What Happened Edward Carr, Chief Accounting Officer of Dianthus Therapeutics (DNTH), exercised three option awards on March 12, 2026 for a total of 43,682 shares (16,182 @ $17.88; 17,500 @ $22.07; 10,000 @ $21.77) at a combined exercise cost of $893,259. The same day he sold those 43,682 shares in multiple open‑market transactions, receiving approximately $3,559,495 in gross proceeds (sales executed at weighted average prices in the $80–$85 range). The pattern is consistent with a cashless exercise followed by an immediate sale rather than a buy as a bullish signal.
Key Details
- Transaction date: March 12, 2026; Form 4 filed March 13, 2026 (appears timely).
- Options exercised: 43,682 shares; total exercise cost reported $893,259.
- Shares sold same day: 43,682 shares; gross proceeds ≈ $3,559,495.
- Large blocks sold at weighted averages: 15,852 @ $80.71 (range $80.30–$81.28), 23,465 @ $81.75 (range $81.30–$82.27), 3,865 @ $82.66 (range $82.34–$83.23); plus smaller lots at $83.38 and $85.53.
- Sales were effected pursuant to a Rule 10b5‑1 trading plan adopted Dec 11, 2025 (footnote F1).
- Vesting notes (F5–F7): the underlying options vest monthly over four years from various grant start dates (Jan 1, 2024; Jan 1, 2025; May 1, 2024).
- The filing shows derivative disposition lines at $0.00 corresponding to the exercised shares (i.e., shares created by exercise were sold).
- Shares owned after the transaction are not specified in the provided excerpt — see the full Form 4 for post‑transaction beneficial ownership.
Context
- This is a routine insider liquidity event (exercise of vested options followed by immediate sale) rather than an open‑market purchase. Sales under a pre‑arranged 10b5‑1 plan typically reduce timing concerns about opportunistic trading, but they do not indicate management’s view of the company’s future performance.
- For retail investors: purchases by insiders generally carry more informational weight than routine option exercises and sales. If you want exact per‑lot sale prices or updated insider holdings, consult the full Form 4 filing (Accession 0001273351-26-000004) or the company’s investor relations disclosures.
Insider Transaction Report
Form 4
CARR EDWARD
CHIEF ACCOUNTING OFFICER
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-12$17.88/sh+16,182$289,334→ 16,182 total - Exercise/Conversion
Common Stock
[F1]2026-03-12$22.07/sh+17,500$386,225→ 33,682 total - Exercise/Conversion
Common Stock
[F1]2026-03-12$21.77/sh+10,000$217,700→ 43,682 total - Sale
Common Stock
[F1][F2]2026-03-12$80.71/sh−15,852$1,279,415→ 27,830 total - Sale
Common Stock
[F1][F3]2026-03-12$81.75/sh−23,465$1,918,264→ 4,365 total - Sale
Common Stock
[F1][F4]2026-03-12$82.66/sh−3,865$319,481→ 500 total - Sale
Common Stock
[F1]2026-03-12$83.38/sh−200$16,676→ 300 total - Sale
Common Stock
[F1]2026-03-12$85.53/sh−300$25,659→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-03-12−16,182→ 63,818 totalExercise: $17.88Exp: 2034-01-23→ Common Stock (16,182 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F6]2026-03-12−17,500→ 42,500 totalExercise: $22.07Exp: 2035-02-03→ Common Stock (17,500 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F7]2026-03-12−10,000→ 50,000 totalExercise: $21.77Exp: 2034-05-22→ Common Stock (10,000 underlying)
Footnotes (7)
- [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.30 to $81.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.30 to $82.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.34 to $83.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- [F6]The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
- [F7]The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Signature
/s/ Adam Veness, as attorney-in-fact for Edward Carr|2026-03-13